A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Summary

This study aimed to evaluate the safety,tolerability and preliminary efficacy of QLF32101 administered intravenously and subcutaneously in patients with R/R, AML.

Timeline

Start

2023-02-01

Primary completion

2024-08-21

Completion

2024-12-21

Drugs

Indications